Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer

1. Gil-Bazo, I.
2. Arévalo, E.
3. Castillo, A.
4. Zudaire, M.E.
5. Carranza, O.E.
6. Fusco, J.P.
7. Castañón, E.
8. Collado-Gómez, V.
9. López, I.
10. Gil-Aldea, I.